Vimarsana
Biggest News Aggregation in the World

Clinical Program Leader News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Program Leader. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Program Leader Today - Breaking & Trending Today

B.C. gives $4.5M to upgrade Vancouver children's hospice - BC - Vimarsana News

B.C. gives $4.5M to upgrade Vancouver children's hospice - BC

Canuck Place was the first children's hospice in North America. Adrian Dix says the changes will make a "real and tangible difference" for children, families and health workers.

Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M.D. as Chief Medical Officer - Vimarsana News

Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M.D. as Chief Medical Officer

/PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address...

Study assesses the acceptance of Medicaid insurance among patients diagnosed with cancers - Vimarsana News

Study assesses the acceptance of Medicaid insurance among patients diagnosed with cancers

Although there has been a significant increase in the number of U.S. residents insured through Medicaid since the expansion of the Patient Protection and Afforadble Care Act (ACA) in March 2010, the ability of Medicaid-insured patients to access cancer care services has not been well understood.

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma - Vimarsana News

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second line therapy extended the length of time patients lived before their disease worsened (progression-free survival) compared with patients who received pomalidomide and dexamethasone.

Alliance for Clinical Trials in Oncology phase I/II study reveals increased progression-free survival for patients - Vimarsana News

Alliance for Clinical Trials in Oncology phase I/II study reveals increased progression-free survival for patients

Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline